 |
|
|
|
|
Letzter Update: 22. Jun. 2011
|
| Morbus Crohn |
| Protocol |
Study drug |
Sponsor |
Status |
Centers |
Schweizer Crohn-/Colitis
Kohortenstudie |
observational study,
no drugs |
SNF |
EC approved
running |
Basel
Bern
Genf
Lausanne
St. Gallen
Zürich |
| Millennium |
Vedolizumab (MLN0002) |
Millennium Pharmaceuticals |
EC approved
running |
Bern
Lausanne
Zürich |
| CALM Study |
Prednison, Azathioprin,
Adalimumab |
Abbott |
EC in progress |
Bern
Zürich |
| TSU-2/CDA |
Trichuris suis ova |
Dr. Falk Pharma |
EC approved |
Bern
Zürich |
| QAX576 |
Anti-IL 13 |
Novartis |
EC approved |
Bern
Lausanne
Zürich |
| |
| Colitis ulcerosa |
| Protocol |
Study drug |
Sponsor |
Status |
Centers |
Schweizer Crohn-/Colitis
Kohortenstudie |
observational study,
no drugs |
SNF |
EC approved
running |
Basel
Bern
Genf
Lausanne
St. Gallen
Zürich |
| M10-223 |
Adalimumab |
Abbott |
EC approved
running |
Bern |
| Millennium |
Vedolizumab (MLN0002) |
Millennium Pharmaceuticals |
EC approved
running |
Bern
Lausanne
Zürich |
| KRP203 |
KRP203 (oraler Sphingosin-1-
Phosphat-Rezeptor-Modulator) |
Novartis |
EC approved |
Basel
Bern
Zürich |
| |
| Ergänzende Studien am USZ - IBD Newsletter als PDF |
